ImmuCell Corp (ICCC) Stock AnalysisICCCImmuCell Corp

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus). It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

ImmuCell Corp is currently not a strong buy due to a recent decline in price and mixed financial performance. The stock is trading at $9.94, which is down 11.33% over the last 20 days, and the RSI is at 37.36, indicating potential oversold conditions. While the company reported a net income of $1,831,656 in Q2 2026, the gross margin has decreased to 33.92% from 43.72% in the previous year, which raises concerns about profitability. The main risk is the 38.9% decline in international sales, which could impact future growth.